Detail akcie TriSals Life Sci Rg online

Business Summary: TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, TriSalus Life Sciences Inc revenues increased 51% to $31.9M. Net loss applicable to common stockholders increased from $22.3M to $61.4M. Revenues reflect Biotechnology & Medical Research segment increase from $14.7M to $31.9M, United States segment increase from $14.7M to $31.9M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 40% to $23.7M.